...
首页> 外文期刊>Endocrine. >Liquid and softgel levothyroxine use in clinical practice: state of the art
【24h】

Liquid and softgel levothyroxine use in clinical practice: state of the art

机译:液体和软凝胶左甲状腺素在临床中的应用:最新技术

获取原文
获取原文并翻译 | 示例
           

摘要

Levothyroxine is recognized as the treatment of choice for hypothyroidism. So far, the tablet levothyroxine has been the formulation almost exclusively used, even though an optimal daily dose of levothyroxine has been unsuccessfully sought and a consensus not achieved. Due to progressive use of a more individually tailored levothyroxine dose, increasing evidence has instead displayed that many gastrointestinal disorders, polypharmacy, and food interference may raise the daily levothyroxineharmacokinetic properties. This study aims to provide an overview regarding the use of softgel capsule and/or liquid levothyroxine solution while performing a review of published studies about such topic. A comprehensive computer literature search of the PubMed/MEDLINE, Scopus, and Google Schol requirement. In recent years, alternative levothyroxine formulations have become available and have rapidly gained attention because of their par databases has been conducted to find published articles on this topic. The search algorithm was based on the combinations of the following terms: "oral solution" or "soft gel" or "liquid", and "levothyroxine". The computer search resulted in 75 articles; through a critical review of such titles and abstracts and a screening of their references lists, the review included 18 original articles relating to 800 patients treated with alternative formulations. Despite some limits, the results obtained using softgel and liquid levothyroxine were consistent with each other. In selected categories of levothyroxine-treated patients (pediatric, suffering from hypo-achlorhydria, polypharmacy, undergone bariatric surgery, fed through enteric tube) these new formulations have shown promising attributes in improving a treatment that needs to be individually tailored.
机译:左甲状腺素被认为是甲状腺功能减退症的治疗选择。迄今为止,即使没有成功寻求左旋甲状腺素的最佳每日剂量,也未达成共识,片剂左旋甲状腺素几乎是唯一使用的制剂。由于逐渐使用了更个性化的左甲状腺素剂量,相反,越来越多的证据表明,许多胃肠道疾病,多种药物和食物干扰都可能会提高左甲状腺素的运动动力学。这项研究旨在概述软胶囊和/或液体左甲状腺素溶液的使用,同时对已发表的有关该主题的研究进行回顾。有关PubMed / MEDLINE,Scopus和Google Schol要求的全面计算机文献搜索。近年来,可供选择的左甲状腺素制剂已经获得并迅速引起关注,因为已经进行了标准数据库的查找以找到有关该主题的文章。搜索算法基于以下术语的组合:“口服溶液”或“软凝胶”或“液体”以及“左甲状腺素”。计算机搜索结果为75条;通过对此类标题和摘要进行严格审查并筛选其参考文献清单,该审查包括18篇原创文章,涉及800例用其他配方治疗的患者。尽管有一些限制,但使用软胶囊和液体左甲状腺素获得的结果彼此一致。在选择的使用左甲状腺素治疗的患者的类别中(小儿,患有胃酸缺乏症,多药治疗,进行减肥手术,通过肠管进食),这些新制剂在改善需要个体定制的治疗方法中显示出了有希望的属性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号